This was a retrospective, cross-sectional analysis using the Medtronic Discovery Link database. 7 All patients with CRT pacing enabled that transmitted data before September 21, 2011, were screened for inclusion. The CRT devices with the latest pacing diagnostics (eg, Concerto, Concerto II, Consulta, Protecta, Protecta XT, and Syncra; Medtronic Inc, Minneapolis, MN) were included. Patients without an atrial lead were excluded. For each patient, data were collected through remote telemetry, with information directly transferred to the Medtronic CareLink network. The information was deidentified and entered in the Discovery Link database. The most recent data transmission that included at least 24 hours of monitoring was selected for analysis. Background-The efficacy of cardiac resynchronization therapy (CRT) is associated with the amount of CRT pacing delivered. The specific causes of CRT pacing loss and their relative frequencies remain poorly defined. Methods and Results-CRT patients who transmitted device data from 2006 to 2011 were screened for inclusion. Device diagnostics were analyzed using an automated algorithm to categorize CRT loss into 10 different causes. The algorithm was validated against manual adjudications using a portion of the entire cohort. There were 80 768 patients analyzed with a median time of 594 (interquartile range, 294-1003) days from implant to time of analysis. In this cohort, 40.7% of patients had <98% pacing, and 11.5% of patients had <90% pacing. For patients with <98% pacing, device diagnostics explained 55.8% of pacing loss: 30.6% atrial tachycardia/atrial fibrillation; 16.6% premature ventricular contractions; and 8.6% captured as episodes with at least 10 consecutive beats of CRT loss (ventricular sensing episodes). Inappropriately programmed sensed and paced atrioventricular (AV) intervals (SAV/PAV) accounted for 34.5% of all ventricular sensing episodes. As the severity of CRT loss increased, the contribution of atrial tachycardia/atrial fibrillation and SAV/PAV to the loss increased. Atrial tachycardia/atrial fibrillation accounted for >50% and premature ventricular contractions accounted for <10% of CRT loss in those with <90% CRT pacing. 
C ardiac resynchronization therapy (CRT) reduces morbidity and mortality in individuals with systolic heart failure and electric dyssynchrony. 1, 2 Unfortunately, ≈30% to 40% of CRT patients do not show clinical improvement. 3 Several factors have been identified to explain this observation. 4 More recently, attention has focused on the importance of maintaining a high degree of CRT pacing. 5 A recent study of a large cohort showed the greatest benefit of CRT in patients receiving an excess of 98% CRT pacing. 6 When loss of CRT pacing is seen, it often occurs as a result of intrinsic ventricular activation superseding biventricular resynchronization. The reasons for intrinsic ventricular activation and their relative prevalence are poorly understood and important to assess because some of them may be amenable to simple treatments that could improve CRT pacing delivery. In addition, developing an automated process with the capability of adjudicating the reasons for intrinsic ventricular activation could facilitate the application of treatments to reduce CRT pacing loss and perhaps improve CRT response. Using a large real-world cohort of individuals with CRT systems enrolled in a remote monitoring program, we leveraged information provided by the device diagnostics related to CRT pacing behavior in an effort to better understand the reasons for CRT pacing loss and their relative prevalence.
Description of Algorithm and Definitions for Reasons for Loss of CRT Pacing
The selected CRT devices have automated diagnostics designed to document CRT pacing delivery and inhibition. The diagnostics include (1) percentage of time with CRT pacing (%CRT) not including left ventricular (LV) pacing triggered by ventricular sensing; (2) percentage of CRT pacing during atrial tachycardia/atrial fibrillation (AT/ AF); (3) hours in AT/AF; (4) average number of premature ventricular contractions (PVCs) and runs of 2 to 4 PVCs per hour; (5) number of occasions where CRT pacing is inhibited for at least 10 consecutive beats (stored as ventricular sensing episodes [VSEs]); and (6) total duration of VSEs. The device is designed to specifically capture VSEs because these episodes represent more sustained periods of CRT loss. See online-only Data Supplement Methods for complete details of the definition of these diagnostics. From these diagnostics, the relative contributions to the total loss of CRT pacing (ie, 100−%CRT) were estimated for each of the 3 broad categories: (1) AT/AF, (2) PVCs, and (3) VSEs. The percentage loss of CRT pacing that occurred during AT/AF was defined as the percentage of CRT pacing loss during AT/ AF multiplied by the fraction of time that the patient was in AT/AF (ie, the hours in AT/AF since last session divided by the hours since last session). The total number of PVCs per hour was estimated by adding the number of single PVCs per hour and 3× the number of PVC runs per hour. (The device detects a PVC run if 2-4 sequential PVCs occur; hence, 3× the number of PVC runs is an estimate of the number of PVCs that occurred for each run.) To estimate the percentage of time without CRT pacing because of PVCs, the total number of PVCs per hour was divided by 3600 seconds per hour and multiplied by an estimated duration of 0.59 seconds per PVC (based on analysis of previously published data). 8 The percentage of time without CRT pacing that was captured in VSEs was determined by dividing the total duration of VSEs by the hours since last session.
Because VSEs are a documentation of lost CRT pacing but not a specific reason for loss of CRT, the algorithm processed the 60 atrial or ventricular event markers stored with each VSE to determine the cause of each VSE (for algorithm details, see the online-only Data Supplement Methods). Table 1 lists the 9 categories of VSE classification. Note that one of the VSE classifications is AT/AF. These are a subset of the broader category of loss of CRT because of AT/AF; specifically, the broader category includes all CRT lost during AT/ AF, whereas VSEs classified as AT/AF include episodes with at least 10 consecutive beats of inhibited CRT because of AT/AF. Thus, overall there were 10 different categories of CRT loss: the 9 categories are listed in Table 1 (with AT/AF considered in a broader context), and the 10th category is PVCs. The VSE classification portion of the algorithm was developed from a database of 418 VSE episodes from 65 patients, which were adjudicated manually according to the classifications in Table 1 . Performance of automated VSE classification was determined based on a separate database of 1207 VSEs from 190 patients, which were adjudicated manually according to the classifications in Table 1 . The algorithm provided classifications for 97.4% of the duration of VSEs, and 98.8% of the total classified duration agreed with manual adjudication.
Statistical Methods
Statistical comparisons between patient subpopulations were conducted via 2-sample t tests for numerical variables and via 2-proportion tests with normal approximation for categorical variables. P<0.05 was considered statistically significant. All statistical computations were performed using SAS version 9.2 statistical software (SAS Institute Inc, Cary, NC).
Results
There were 80 768 patients who met the inclusion criteria for the database. The data transmissions occurred between October 7, 2006, and September 20, 2011. The patients were predominantly men (73.1%) with an average age of 72.3±11.6 years. The median follow-up duration per transmission was 76.0 (interquartile range, 28.1-93.9) days, and there was a broad distribution of durations between device implant and the selected transmission date for analysis (median, 594 [interquartile range, 294-1003] days). CRT-P devices accounted for 0.2% of the cohort. Rate-responsive pacing was enabled in 68.5% of patients, and pacing modes with atrial tracking (DDD/ DDDR) were programmed in 92.5% of patients. An AT/AF burden of <1% was observed in 78.0% of the patients, and an AT/AF burden of >90% was observed in 14.7% of the patients. Figure 1 summarizes the %CRT pacing in the entire cohort: 40.7% of patients had <98% CRT pacing, and 11.5% of patients had <90% CRT pacing.
For the 32 844 patients with <98% CRT pacing, the automated analysis of device diagnostics accounted for 55.8% of the total loss of CRT. As shown in Figure 2 , 30.6% of lost CRT occurred during AT/AF, PVCs accounted for 16.6% of lost CRT, and 8.6% of lost CRT was captured in VSEs. Interestingly, the contribution of AT/AF, PVCs, and the combined reasons for VSEs to the loss of CRT varied according to the categorized percent of CRT pacing. AT/AF was a larger contributor to the loss of CRT in those patients with a greater reduction of CRT. In patients with 95% to 98% CRT, 19.2% of the loss of CRT occurred during AT/AF, whereas in Table 1 patients with <90% CRT, 51.8% of the loss of CRT occurred during AT/AF. In contrast, PVCs were a smaller contributor to the loss of CRT in those patients with a greater reduction of CRT. PVCs contributed an estimated 20.9% of the loss of CRT in patients with 95% to 98% CRT pacing but only 9.5% of the loss of CRT in patients with <90% CRT pacing. This trend occurred despite an increase in the number of PVCs per hour from 45.0 for patients with 95% to 98% CRT to 103.3 for patients with <90% CRT. The proportion of loss of CRT that was captured in VSEs increased slightly from 7.2% for patients with 95% to 98% CRT to 12.2% for patients with <90% CRT.
Sustained Periods of CRT Loss (VSEs)
A total of 193 737 VSEs were obtained in patients with <98% CRT pacing. Figure 3 summarizes the duration-weighted automated classifications of the VSEs. Overall, intrinsic ventricular conduction because of long programmed values of sensed atrioventricular (SAV)/paced atrioventricular (PAV) interval accounted for the largest portion of VSE duration (34.5%). Looking over the categories of %CRT pacing, the contribution of long programmed values of SAV/PAV to the duration of VSEs was minimal for patients with 95% to 98% CRT (5.4%) but became dominant for patients with <90% CRT (45.6%). In contrast, the contribution of supraventricular tachycardia/ sinus tachycardia to the duration of VSEs was dominant for patients with 95% to 98% CRT (26.9%) but became minimal for patients with <90% CRT (3.6%). The overall contribution of AT/AF to the duration of VSEs was 19.6%. The VSEs that were obtained during AT/AF were a subset of the overall loss of CRT during AT/AF; specifically, VSEs contain the subset that included at least 10 consecutive beats without CRT pacing. Idioventricular rhythm and ventricular tachycardia accounted for 9.9% of overall VSE duration but peaked at 19.1% for patients with 90% to 95% CRT pacing. Loss of CRT pacing because of a programmed nontracking mode of pacing (DDI/R or VVI/R) accounted for 7.8% of the duration of VSEs, almost all occurring in patients with <90% CRT. This latter category was included as a reason because it reflected a potential error of device programming, similar to programming a suboptimal upper tracking rate or SAV/PAV interval.
Given the predominant role of SAV/PAV in accounting for periods of at least 10 beats of CRT loss, we further evaluated whether the programmed SAV/PAV intervals and use of rateadaptive atrioventricular (RAAV) pacing differed between patients who did and patients who did not have VSEs caused by SAV/PAV ( Table 2) . Patients who had VSEs caused by SAV/PAV had substantially longer programmed SAV and PAV (P<0.00001) and were less likely to have RAAV programmed on (P<0.00001).
Discussion
By analyzing existing device-based diagnostics, our efforts to better understand the reasons for loss of CRT pacing resulted in 3 important findings. In a large cohort of real-world patients with CRT systems, 40.7% of patients exhibited <98% CRT pacing. Second, the specific reasons for the loss of CRT pacing varied depending on the overall percentage of pacing. Although AT/AF accounted for the largest portion of CRT loss in all patients with <98% CRT pacing, its contribution to CRT pacing loss diminished as the amount of CRT pacing approached 98%. In fact, PVCs played a larger role in the loss of CRT pacing as overall pacing percentages approached 98%. Last, the largest contributor to more sustained loss of CRT pacing (ie, VSEs containing at least 10 consecutive beats without CRT) was inappropriate programming of SAV/PAV intervals and lack of using RAAV. These findings help shed light on the most common causes for suboptimal CRT pacing as a function of the degree of lost CRT pacing. More importantly, these data could lead to corrective actions and possibly improved CRT response. To facilitate corrective actions, automated algorithms like the one used here could be applied to each data transmission, resulting in a report of the severity of CRT loss and the determined reasons for CRT loss. Currently, observations are made automatically only if CRT pacing is <90%. In addition, no further assistance is provided for interpreting CRT pacing diagnostics.
Efforts Aimed at Improving CRT Delivery
Appropriate corrective actions exist for certain causes of CRT loss, and our data suggest that the majority of CRT loss episodes can be readily corrected. AT/AF can be ablated or pharmacological rhythm or rate control may be effective for improving the CRT pacing percentages. Pacing algorithms that minimally overdrive ventricular rate during AT/AF may also increase CRT pacing during AT/AF. Atrioventricular node ablation is a final option, and recent reports suggest that increasing CRT pacing through ablation of the atrioventricular node incrementally improves CRT outcomes, despite a lack of atrioventricular synchrony. [9] [10] [11] CRT loss from sinus tachycardia can be resolved by increasing the upper tracking rate. CRT loss from atrial undersensing, ventricular oversensing, or nontracking pacing modes can be resolved by appropriate device programming or lead revisions. CRT loss from PVCs may also respond to ablation or antiarrhythmic medications. 12, 13 Last, CRT loss because of SAV/PAV can be readily resolved by modifying the programmed SAV/PAV intervals or perhaps application of RAAV. Based on our analysis, inappropriately programmed SAV/PAV intervals was the predominant reason for sustained episodes in which loss of CRT pacing was observed. It is interesting to speculate on the reasons for this. In many cases, adjustment of the programmed SAV/PAV intervals is guided by hemodynamic data derived from echo-based modalities or automated device-based systems. When changes are made, they more commonly result in lengthening of the SAV/PAV intervals from their nominal settings.
14 Although these changes may be beneficial in a resting state, this may undermine the ability of CRT systems to pace in the setting of increased adrenergic tone. It remains unclear whether hemodynamic optimization at rest, done at the expense of potentially reducing overall CRT pacing percentages, justifies this practice in the future. As our data suggest, perhaps the use of applications such as RAAV may play a greater role in the future management of these patients.
Limitations
Several limitations affected our analysis. Because this was a database analysis from CareLink, we do not have extensive information about clinical patient demographics, such as heart failure status, nor what interventions were used in each patient. By analyzing a cohort of >80 000 individuals, we believe that these results remain pertinent to the greater population of patients with these devices. Although safety margins for LV pacing and predominant use of daily automated LV capture management minimized loss of LV capture, it was not possible to account for loss of LV capture as a possible reason for loss of CRT pacing. Inherent limitations in the device diagnostic algorithms also prevented us from explaining every beat without CRT. Specifically, VSEs capture any occurrence of ≥10 consecutive beats of inhibited CRT pacing. However, episodes with <10 consecutive beats of inhibited CRT are not documented. Also, PVC detection in these devices requires short coupling intervals (R-R intervals that are <69% of prior intervals). PVCs with longer coupling intervals are not documented. In addition, a given episode of CRT loss was attributed to a single reason, and it is possible that some occasions of CRT loss occurred for >1 reason (ie, PVCs occurring during AT/AF or rapidly conducted AT/AF during a nontracking pacing mode were both categorized simply as AT/AF). Our manual review of 1207 VSEs suggests that this is rare. Finally, device diagnostics for CRT pacing describe the quantity of CRT pacing but do not address the quality of CRT pacing. Varying degrees of fusion and pseudofusion may provide variable benefit of CRT pacing 15 but are all reported equally as CRT pacing by device diagnostics.
Conclusions
In a large cohort of CRT patients, 40.7% of patients had <98% pacing. AT/AF accounted for the largest portion of CRT loss, a portion that increased as the overall %CRT pacing decreased. The largest contributor to sustained periods without CRT was inappropriate programming of SAV/PAV intervals. Many 
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